SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

$SPERMWHALE is trending as investors actively discuss its potential for rapid price surges, utility features like buybacks, and its status within the volatile meme coin community. The conversation is driven by a mix of speculative enthusiasm for breaking new all-time highs and persistent debate regarding the project's sustainability compared to other emerging tokens.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as community members highlight its role as a core infrastructure player in the growing AI-crypto sector, with many traders accumulating positions in anticipation of a significant breakout. Discussion is focused on the protocol's utility in AI-Intents and cross-chain functionality, with bullish sentiment driven by long-term holders despite periods of price volatility.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community maintains a patient, long-term outlook, frequently discussing the project's potential for future growth despite recent price consolidation. Supporters are actively engaging with the ecosystem's utility, including staking options and the health-focused rewards model, while some users look forward to a potential long-term turnaround for the token.

SkyAI is an all-in-one AI ecosystem powered by MCP, designed to seamlessly integrate intelligent solutions across industries.

SkyAI

SkyAI is experiencing significant market momentum and bullish sentiment, with investors actively comparing its recent price action and volume levels to other high-performing crypto assets. Community discourse centers on the coin's rapid ascent into top rankings and the potential for a continued breakout as traders look for the next major growth cycle.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing market attention as it gains traction on Base, fueled by the integration of AI-driven DeFi execution tools and expanded accessibility through recent exchange listings. The community remains highly active, debating the potential for long-term utility-driven growth while navigating the volatility inherent in speculative trading.

Liquid Mercury is a technology company that provides institutional-grade trading infrastructure, workflow automation, and Real World Asset (RWA) marketplaces. Its platform is designed to meet the performance, security, and reporting standards expected by the most demanding traditional finance institutions.  At the core of the ecosystem is MERC, an ERC-20 utility token that delivers value to users in three primary ways:  1. Discount Farming via Staking  MERC holders can participate in a “Discount Farming Staking Program,” which enables users to earn monthly Element Tokens (ETs) by staking their MERC tokens. These ETs can be:  - Applied toward Liquid Mercury invoices for service discounts, if you're a customer. - Traded for cash equivalents on a private secondary marketplace where ET holders and Liquid Mercury customers can buy and sell ETs.  2. Access to Premium Features and Staking Rewards  Staking MERC also unlocks:  - Access to exclusive research, curated trading tools, and trading rebates. - Annual staking rewards paid in MERC, currently set at 10% per year.  3. Utility in the Expansion of Real World Asset (RWA) Markets  As Liquid Mercury grows its footprint in the RWA sector, the role of the MERC token will expand accordingly, powering participation and utility within tokenized asset marketplaces.

Liquid Mercury

Liquid Mercury is gaining traction as community members highlight continuous development updates, including new website features and the TokenBloq integration. Investors are actively tracking the project's institutional-grade infrastructure and its high-profile backing as part of broader ecosystem partnerships.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community closely monitors legislative developments around the Clarity Act, which many believe will solidify the token's status as a digital commodity and drive institutional adoption. While some investors are aggressively accumulating in anticipation of a major run, ongoing debates between banking interests and crypto proponents continue to fuel both optimistic speculation and skepticism regarding the project's long-term utility.

What is Chronotech? Chrono.tech provides blockchain-based solutions for recruitment, HR and payment processes, reducing the barriers to accessing work and transferring funds securely in the global labor marketplace. The project’s suite of services - and native governance token TIME - are hosted on multiple blockchains and include LaborX.com, a peer-to-peer freelancer marketplace, TimeX.io, a Plasma-based cryptocurrency exchange; AUDT, an Australian dollar-backed stablecoin; and PaymentX, a crypto invoicing and payroll solution.  TIME token The TIME token is the native token of the Chrono.tech ecosystem and can be used within its products, e.g. to secure premium account status, as well as staking TIME on TimeWarp.finance to receive the revenues generated by all services. In November 2020, the original TIME token was upgraded to the new ERC677 standard, enabling it to be integrated with other DeFi protocols, allowing lower-cost transactions, and providing other advantages, while remaining fully ERC20-compatible. The new TIME 2.0 token contract also included up-to-date metadata about the project.  Chrono.tech products and ecosystem Chrono.tech aims to solve a series of problems in the global recruitment and employment markets. LaborX is Chrono.tech’s freelance work portal. The service allows freelancers and customers to organise work via digital agreements, powered by smart contracts. All payments are escrowed and made in cryptocurrency. Once a job is completed, escrowed payments are released automatically. A dispute resolution service is available in case of disagreement. TimeX is Chrono.tech’s cryptocurrency exchange. TimeX is a hybrid Plasma-based exchange that offers the benefits of both centralised and decentralised technologies. Use of Plasma allows for fast, secure trading of digital assets. The conventional interface provides a user-friendly trading experience. Based in Australia, TimeX is licensed and compliant with rules and best practices required by AUSTRAC, the country’s financial intelligence agency. TimeX is listed on CoinMarketCap https://coinmarketcap.com/exchanges/timex/ TimeWarp is the ecosystem’s DeFi yield farming application where TIME holders can stake their token to earn revenues generated by all products of the Chrono.tech product range. All 100% of revenues generated are being distributed to TIME holders on a weekly basis. AUDT is a stablecoin, hosted on the Ethereum blockchain and backed 1:1 with Australian dollars (AUD). Use of AUDT enables traders to move money into and out of the blockchain ecosystem from an Australian bank account, to store value in AUD on the blockchain and transfer funds anywhere in the world, quickly and easily. AUDT is one of the key fiat currencies traded on TimeX. AUDT is fully compliant with AUSTRAC requirements and undergoes regular audits conducted by a licensed, third party accounting firm. PaymentX is a multi-currency crypto payroll solution that enables individuals as well as businesses to integrate crypto payments into their day-to-day invoice processes. Contractors can submit professional invoices and specify a crypto wallet for payment. Companies can pay multiple invoices with one click, while the software converts the dollar-equivalent amount due into crypto automatically at the point of transaction, avoiding the need for manual calculations. TimeBridge is an in-house developed multi-blockchain tokenbridge that supports multiple blockchains such as Ethereum and BSC. It allows transferring of TIME tokens between networks.

Chronobank

Chronobank is currently generating significant social media conversation driven by its extremely low circulating supply and community-led efforts to create scarcity through buybacks and token burns. Investors are actively debating the asset's potential for volatile price swings, with many highlighting its history of rapid spikes and viewing current price levels as a strategic entry point.

Peanut the Squirrel Markets

PNUT is seeing heightened social media activity as traders speculate on its potential for a breakout, driven by the broader meme coin rotation and optimism surrounding crypto market sentiment. The community is actively debating the token's long-term potential compared to other popular memes, while monitoring key support levels and price action for signs of an impending move.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a focal point for the community as investors debate the impact of potential burn mechanisms and the long-term viability of the chain's revival efforts. Discussions are heavily divided between those highlighting bullish technical patterns and opportunistic accumulation strategies, and others dismissing the asset as a speculative pump-and-dump venture.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire SARASOTA, Fla...

Biotech Stocks To Keep An Eye On - April 26th

Danaher, Vertex Pharmaceuticals, Medpace, argenex, Moderna, Enveric Biosciences, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science and technology to develop drugs, th...

<ul class="summary-bullets"><li>While the S&amp;P 500 closed up about 0.8% on Friday, the Nasdaq Composite rose 1.63%.&nbsp;</li><li>Trump announcements and solid corporate earnings drove significant rallies this week.</li></ul>U.S. equities closed out a highly active week on Friday, with the S&amp;P 500 and Nasdaq Composite ending the week near all-time highs, supported by strong earnings in the chipmaking and AI space, while policy support for cannabis and psychedelic research drove a few mid and small-cap pharma stocks higher.While the S&amp;P 500 closed up about 0.8% on Friday, marking its fourth consecutive week of gains, the Nasdaq Composite rose 1.63%. &nbsp;The following stocks clocked the highest gains this week:Akanda Corp. (<a href="https://stocktwits.com/symbol/AKAN">AKAN</a>): Shares of Akanda exploded this week, surging more than 300% after the Trump administration advanced plans to reclassify marijuana as a Schedule III drug. The broader cannabis sector ignited on the policy shift, and AKAN recorded single-day gains as high as 214%.Enveric Biosciences (<a href="https://stocktwits.com/symbol/ENVB">ENVB</a>): ENVB shares rocketed higher early in the week after President Trump’s executive order directing federal agencies to accelerate research and approval pathways for psychedelic therapies. The small-cap developer of psychedelic medicines for mental health surged more than 100% in a single session as investors bet on faster regulatory tailwinds in the sector. The company clocked its best week ever.MaxLinear (<a href="https://stocktwits.com/symbol/MXL">MXL</a>): MXL climbed sharply after the semiconductor company delivered a strong first-quarter earnings beat on Thursday and issued upbeat guidance that highlighted robust demand for its optical and connectivity chips in AI data centers. Revenue rose 43% year-over-year, beating estimates, and the raised outlook for the current quarter sent shares surging more than 75% in Friday’s session. The stock closed 130% higher this week, marking its best week to date.Trio-Tech International (<a href="https://stocktwits.com/symbol/TRT">TRT</a>): TRT stock soared as much as 67% on Thursday to a new all-time high as momentum traders piled into the stock. The company provides reliability testing services and specialized equipment that help chipmakers validate and stress-test products before they reach customers amid an overall increase in chip demand driven by AI infrastructure and data centers. The stock closed at $16.52 on Friday, after opening at just $7.05 at the week’s onset.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/arwr-rallies-this-week-as-europe-edges-closer-to-redemplo-approval-amid-analyst-optimism/cZBhLOHRecF">ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of GNTX rise on Friday (Representative image: Getty Images)

Cannabis, Psychedelics, And AI Stocks Are Wall Street’s Biggest Winners This Week

AKAN, ENVB, MXL, and TRT were the biggest gainers in the week ended April 24. 

Equity

AKAN, ENVB, MXL, and TRT were the biggest gainers in the week ended April 24. 


What's Going On With Enveric Biosciences Stock On Friday?

The FDA issues priority vouchers and clears early trials for ibogaine derivatives for using psychedelics for therapy and mental health.read more...

Biotech Stocks To Add to Your Watchlist - April 24th

Danaher, Enveric Biosciences, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

<ul class="summary-bullets"><li>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.</li><li>The agency stated that it has also cleared DemeRx NB’s early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug submission.</li><li>Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.</li></ul>The U.S. Food and Drug Administration (FDA) on Friday announced several regulatory actions to accelerate the development of psychedelic treatments aimed at serious mental health issues.The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” said Health and Human Services Secretary Robert F. Kennedy, Jr.This comes after President Trump signed an executive order last week that directed health agencies to speed up research on drugs like psilocybin, MDMA, and ibogaine.Shares of&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) skyrocketed over 62% in Friday morning’s trade, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways Plc.</a> (CMPS) and&nbsp;<a href="https://stocktwits.com/symbol/HELP">Helus Pharma Inc.</a> (HELP) and&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) rose between 2% to 3%.<h2 class="st-heading-2">FDA To Issue National Priority Vouchers</h2>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.The agency stated that it has also cleared an early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug (IND) submission.This is the first time the FDA has permitted a U.S.-based clinical study of an ibogaine derivative, enabling the developer of the novel therapy, DemeRx NB, to initiate a Phase 1 trial in a closely monitored clinical setting in the United States.RFK Jr. said the agency will prioritize therapies with Breakthrough Therapy designation, for which early evidence shows meaningful improvement over existing options for serious mental illness.The agency stated that its decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective. FDA added that it will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is up 36% year-to-date,&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> is down 33%, while&nbsp;<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is up 77%.The AdvisorShares Psychedelics ETF (PSIL) is up 68% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans. (Photo by Allison Robbert/For The Washington Post via Getty Images)

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Enveric Biosciences to Participate in a Panel Discussion at Needhams Virtual Psychedelics Forum

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Top Small Cap Stocks To Keep An Eye On - April 20th

Spring Valley Acquisition, Enveric Biosciences, and Psyence Biomedical are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small cap stocks are shares of...

Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order

Enveric BioSciences Inc. shares are soaring on Monday after President Trump order to accelerate approvals for psychedelic treatments.read more...

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ENVB News

ENVBEnveric Biosciences Inc